Current Report Filing (8-k)
11 February 2022 - 9:09AM
Edgar (US Regulatory)
0001263364
false
0001263364
2022-02-03
2022-02-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 3, 2022
Joway Health Industries Group Inc.
(Exact Name of Registrant as Specified in Charter)
Nevada
|
|
333-108715
|
|
98-0221494
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
600
South 3rd Street
Las Vegas, Nevada
|
|
89101
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: 702-384-1990
No. 2, Baowang Road, Baodi Economic Development
Zone
Tianjin, PRC 301800
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act: None
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
None
|
|
N/A
|
|
None
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry Into a Material Definitive Agreement.
Change in Control
On February 3, 2022,
Joway Health Industries Group Inc., a Nevada corporation, (the “Company”), consummated the transactions contemplated by the
Stock Purchase Agreement dated as of January 31, 2022 (the “Purchase Agreement”), by and among the Company, Crystal Globe
Limited, a company incorporated under the laws of British Virgin Islands (the “Seller”), and JHP Holdings, Inc., a Nevada
corporation (the “Buyer”), pursuant to which the Buyer purchased 16,644,820 shares of common stock of the Company from the
Seller. The shares represent 83% of the issued and outstanding shares of the Company on a fully diluted basis. The purchase price for
the shares paid by the Buyer was $100,000. Pursuant to the Purchase Agreement, each of the Seller, Buyer and Company made customary representations
and warranties to each other. The parties agreed to certain customary post-closing covenants, including those relating to confidentiality,
publicity and litigation support. The Company and Seller also agreed to certain indemnification provisions as they pertain to the Buyer
for breaches or inaccuracies in their respective representations and warranties or covenants.
In connection with the
acquisition of the 83% by the Buyer, Jinghe Zhang, the sole officer and director of the Company, resigned and the Buyer appointed Ramon
Lata as the sole officer and director of the Company.
The foregoing description
of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase
Agreement which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
As a result of the closing of these stock purchase transactions, the
control of the Company has been transferred from the Seller to the Buyer, a company owned and controlled by Mr. Lata.
Shell Company Status; Change of Business Plan
The Company is a shell company, as that term is defined in Rule 12b-2
of the Securities Exchange Act of 1934, as amended, and will remain a shell company for the foreseeable future. The Company will promptly
file a Current Report on Form 8-K when, and if, its status as a shall company changes.
The Company has no specific plans or proposals at this time which relate
to or would result in:
|
●
|
the acquisition by any person of additional securities of the Company;
|
|
●
|
an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries;
|
|
●
|
a sale or transfer of a material amount of assets of the Company or of any of its subsidiaries;
|
|
●
|
any material change in the present capitalization or dividend policy of the Company;
|
|
●
|
any other material change in the Company's business or corporate structure;
|
|
●
|
changes in the Company's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of
control of the issuer by any other person;
|
|
●
|
causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be
quoted in an inter-dealer quotation system of a registered national securities association;
|
|
●
|
a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the
Securities Act of 1933, as amended; or any similar action to those enumerated above.
|
Item 5.02
Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
In connection with the closing of the stock purchase transactions discussed
above, effective as of February 2, 2022, Jinghe Zhange resigned from his position as sole officer and director of the Company. The resignation
of Mr. Zhange was not in connection with any known disagreement with the Company on any matter.
On February 2, 2022, Mr. Ramon Lata was appointed to the board of the
directors upon the resignation of Mr. Zhang. Mr. Lata was also appointed as the President, Treasurer and Secretary of the Company. The
Company and the newly appointed officer have not entered into any arrangement regarding the payment of compensation for acting as an officer
or director of the Company.
Since December 2021, Ramon Lata has been a vice president at Wilhelmina
International, a model and talent agency. Mr. Lata was a vice president at Factor Chosen LLC from April 2015 until September 2017, when
it was acquired by MP Management. From September 2017 until November 2019, Mr. Lata was a vice president at Select Model LA., until it
was acquired by MP Management.
There are no arrangements or understandings between Mr. Lata and any
other persons pursuant to which he was selected as an officer. Mr. Lata was appointed until his successor is duly elected and qualified.
There has been no transaction, nor is there any currently proposed transaction between Mr. Lata and the Company, that would require disclosure
under Item 404(a) of Regulation S-K.
Item
9.01 Financial Statements and Exhibits.
Financial Statements and Exhibits
(d)
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: February 10, 2022
|
Joway Health Industries Group Inc.
|
|
|
|
|
By:
|
/s/ Ramon Lata
|
|
|
Ramon Lata
|
|
|
President
|
3
Joway Health Industries (PK) (USOTC:GTVI)
Historical Stock Chart
From Apr 2024 to May 2024
Joway Health Industries (PK) (USOTC:GTVI)
Historical Stock Chart
From May 2023 to May 2024